This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jun 27;486(7404):482-3.

doi: 10.1038/486482a.

Cancer: Pinprick diagnostics

Eduardo Vilar, Josep Tabernero

PMID: 22739312
DOI: 10.1038/486482a

Comment

Cancer: Pinprick diagnostics

Eduardo Vilar et al. Nature. 2012.

. 2012 Jun 27;486(7404):482-3.

doi: 10.1038/486482a.

Authors

Eduardo Vilar, Josep Tabernero

PMID: 22739312
DOI: 10.1038/486482a

No abstract available

PubMed Disclaimer

Comment on

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Misale S, et al. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156. Nature. 2012. PMID: 22722830 Free PMC article.
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. Diaz LA Jr, et al. Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219. Nature. 2012. PMID: 22722843 Free PMC article.

Similar articles

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Misale S, et al. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156. Nature. 2012. PMID: 22722830 Free PMC article.
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. Diaz LA Jr, et al. Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219. Nature. 2012. PMID: 22722843 Free PMC article.
KRAS assay selection: sensitivity and accuracy in clinical application.
Herreros-Villanueva M, Aggarwal G. Herreros-Villanueva M, et al. Mol Biol Rep. 2012 Mar;39(3):2467-70. doi: 10.1007/s11033-011-0997-6. Epub 2011 Jun 9. Mol Biol Rep. 2012. PMID: 21656377
Anti-EGFR therapy in colorectal cancer: how to choose the right patient.
Meriggi F, Di Biasi B, Abeni C, Zaniboni A. Meriggi F, et al. Curr Drug Targets. 2009 Oct;10(10):1033-40. doi: 10.2174/138945009789577891. Curr Drug Targets. 2009. PMID: 19663767 Review.
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Mancl EE, Kolesar JM, Vermeulen LC. Mancl EE, et al. Am J Health Syst Pharm. 2009 Dec 1;66(23):2105-12. doi: 10.2146/ajhp090036. Am J Health Syst Pharm. 2009. PMID: 19923311 Review.

See all similar articles

Cited by

Tumour heterogeneity: principles and practical consequences.
Stanta G, Jahn SW, Bonin S, Hoefler G. Stanta G, et al. Virchows Arch. 2016 Oct;469(4):371-84. doi: 10.1007/s00428-016-1987-9. Epub 2016 Jul 13. Virchows Arch. 2016. PMID: 27412632 Review.
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.
Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Parseghian CM, et al. Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509. Ann Oncol. 2019. PMID: 30462160 Free PMC article.
Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib.
Melosky B. Melosky B. Asia Pac J Oncol Nurs. 2016 Jan-Mar;3(1):58-65. doi: 10.4103/2347-5625.178174. Asia Pac J Oncol Nurs. 2016. PMID: 27981140 Free PMC article. Review.
Overview on Clinical Relevance of Intra-Tumor Heterogeneity.
Stanta G, Bonin S. Stanta G, et al. Front Med (Lausanne). 2018 Apr 6;5:85. doi: 10.3389/fmed.2018.00085. eCollection 2018. Front Med (Lausanne). 2018. PMID: 29682505 Free PMC article. Review.
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
García-Alfonso P, García-Foncillas J, Salazar R, Pérez-Segura P, García-Carbonero R, Musulén-Palet E, Cuatrecasas M, Landolfi S, Ramón Y Cajal S, Navarro S; Spanish Society of Pathology; Spanish Society of Medical Oncology. García-Alfonso P, et al. Clin Transl Oncol. 2015 Apr;17(4):264-73. doi: 10.1007/s12094-014-1252-0. Epub 2014 Nov 6. Clin Transl Oncol. 2015. PMID: 25373533

See all "Cited by" articles

References

1. Nature. 2012 Jun 28;486(7404):537-40 - PubMed
1. Nat Methods. 2006 Jul;3(7):551-9 - PubMed
1. Nat Med. 2012 Jan 22;18(2):221-3 - PubMed
1. Nature. 2012 Jun 28;486(7404):532-6 - PubMed
1. Nat Med. 2008 Sep;14(9):985-90 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal